



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

October 9, 2002
Date


Shelley P.M. Fussey

TECH CENTER 1600/2900

OCT 18 2002

RECEIVED

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Smythe, Meutermans, Bourne and McGeary

Serial No.: 09/806,036

Filed: March 22, 2001

For: Synthesis of Cyclic Peptides

Group Art Unit: 1646

Examiner: Unknown

Atty. Dkt. No.: 4050.001200

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be required. Even if an Official Action had been issued in the last few days, no fees would be required in light of the following information.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the present statement. This is evidenced by the date on the enclosed and listed Partial Supplementary European Search Report.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4050.001200.

Respectfully submitted,


Shelley P.M. Fussey
Reg. No. 39,458
Agent for Applicants

WILLIAMS, MORGAN & AMERSON, P.C.
7676 Hillmont, Suite 250
Houston, Texas, 77040
(713) 934-4079

Date: October 9, 2002

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

4050.001200

09/806,036

List of Patents and Publications for Applicant's

Applicant
Smythe et al.

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

March 22, 2001

Group:

1646

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
	C6	Sakurada <i>et al.</i> , "Antinociceptive Mechanisms of [D-Arg ²]-Dermorphin Tripeptide Analogs," <i>J. Pharm. Exp. Thera.</i> , 263(2):793-799, 1992.
	C7	Salvadori <i>et al.</i> , "Synthesis and Pharmacological Activity of Dermorphin and its N-Terminal Sequences," <i>Int. J. Peptide Protein Res.</i> , 19:536-542, 1982.
	C8	Partial Supplementary European Search Report for European Counterpart Application No. 99948610.3, mailed September 12, 2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



RECEIVED

OCT 1 8 2002

TECH CENTER 1600/2900